<DOC>
	<DOCNO>NCT00027365</DOCNO>
	<brief_summary>The purpose study see investigational vaccine NefTat gp120w61d safe tolerable human see immune system respond vaccine . There advance treatment prevention HIV , spread HIV/AIDS get bad . HIV/AIDS main infectious cause death world . A vaccine prevent HIV disease best way try deal situation . Several vaccine product test , 2 still trial . There need new product .</brief_summary>
	<brief_title>An Investigational Combination Vaccine Given People Who Are Not Infected With HIV</brief_title>
	<detailed_description>Despite recent advance treatment prevention HIV disease , epidemic worsen throughout world . HIV/AIDS lead cause death sub-Saharan Africa lead infectious cause death world . An effective inexpensive vaccine prevent HIV disease remain best option try deal expand epidemic . A number vaccine product test ; however , 2 progress Phase III trial , underscore need new vaccine strategy . Prior study entry , participant risk status HIV infection determine series question . Further eligibility determine result physical exam , laboratory test , question . Blood drawn study visit . Participants assign randomly 1 4 study group : Group I : NefTat placebo . Groups II , III , IV : NefTat gp120 placebo . Each group receive different concentration gp120 . All immunization admix AS02A adjuvant . Vaccinations administer intramuscularly 3 time point ( entry , 1 month , 3 month ) . Product safety immunogenicity perform designated time point ; participant 11 clinic visit .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Participants may eligible study : Are 18 60 year age . Are good general health meet laboratory test requirement . Have CD4 count 400 cells/mm3 . Agree use least 1 follow method contraception least 21 day enrollment last protocol visit : condom ( male female ) without spermicide , diaphragm cervical cap spermicide , IUD , hormonalbased therapy ( applies woman able child ) . Have access participate site willing followup entire study ( 12 month ) . Answer question understand study . Do hepatitis B C. Are HIVuninfected . Exclusion Criteria Participants may eligible study : Are pregnant breastfeeding . Have recently receive vaccine . Have use experimental agent within 30 day enrollment . Have receive HIV vaccine placebo previous HIV vaccine study . Have receive blood product 120 day HIV screening . Have receive immunoglobulin ( antibody ) 60 day HIV screening . Have serious reaction vaccine . Have problem immune system . Have cancer . Have use drug affect immune system within past 6 month . Have diabetes . Have thyroid disease . Have unstable asthma . Are take antituberculosis drug . Have seizure . Have bleed disorder . Have spleen remove . Have angioedema ( certain type body tissue swell ) . Have active syphilis . Have high blood pressure ( unless control medication ) . Have mental emotional problem make unsuitable study . Have medical , mental , social condition ; job responsibility ; responsibility , opinion doctor , would interfere study . Have reaction component vaccine . Are high risk contract HIV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
	<keyword>Injections , Intramuscular</keyword>
	<keyword>HIV Antibodies</keyword>
	<keyword>HIV-1</keyword>
	<keyword>HIV Envelope Protein gp120</keyword>
	<keyword>Gene Products , tat</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>Neutralization Tests</keyword>
	<keyword>Vaccines , Combined</keyword>
	<keyword>AIDS Seronegativity</keyword>
	<keyword>Gene Products , nef</keyword>
</DOC>